The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedInitial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Self-citationThe Proteasome: Paradigm of a Self-Compartmentalizing Protease
Baumeister, W., Walz, J., Zühl, F., & Seemüller, E. (1998) · Cell · doi:10.1016/s0092-8674(00)80929-0 · Cited by 1,494
Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Brca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
Cited by
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Regulation of DNA double-strand break repair pathway choice
Shrivastav, M., De Haro, L. P., & Nickoloff, J. A. (2008) · Cell Research · doi:10.1038/cr.2007.111 · Cited by 1,329
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., & Jasin, M. (2011) · Cell · doi:10.1016/j.cell.2011.03.041 · Cited by 1,255
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Self-citationRottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
Moynahan, M. E., & Jasin, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2851 · Cited by 930
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Self-citationMutation as a Stress Response and the Regulation of Evolvability
Galhardo, R. S., Hastings, P. J., & Rosenberg, S. M. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701648502 · Cited by 643
“Similarly, the BRCA1 gene, which functions in HR-DSBR and suppresses use of the more error-prone NHEJ pathway of DSBR (reviewed by Gudmundsdottir and Ashworth, 2006), is also transcriptionally down-regulated by repressive E2F complexes (Bindra et al., 2005).”
BackgroundThe impact of a negligent G2/M checkpoint on genomic instability and cancer induction
Löbrich, M., & Jeggo, P. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2248 · Cited by 632
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Melo, J. V., & Barnes, D. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2147 · Cited by 623
PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Sy, S. M. H., Huen, M. S. Y., & Chen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811159106 · Cited by 614
Ionizing Radiation-Induced DNA Damage, Response, and Repair
Santivasi, W. L., & Xia, F. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5668 · Cited by 593
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Li, H., Liu, Z.-Y., Wu, N., Chen, Y.-C., Cheng, Q., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01227-0 · Cited by 539
Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks
Galanty, Y., Belotserkovskaya, R., Coates, J., Polo, S., Miller, K. M., & Jackson, S. P. (2009) · Nature · doi:10.1038/nature08657 · Cited by 523
Beyond chemotherapy: targeted therapies in ovarian cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2583 · Cited by 495
The emerging landscape of breast cancer susceptibility
Stratton, M. R., & Rahman, N. (2008) · Nature Genetics · doi:10.1038/ng.2007.53 · Cited by 487
Basal-like breast cancer and the BRCA1 phenotype
Turner, N. C., & Reis-Filho, J. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209876 · Cited by 478
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Dev, H., Chiang, T.-W. W., Lescale, C., de Krijger, I., Martin, A. G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0140-1 · Cited by 417
Thompson, L. H. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2012.06.002 · Cited by 357
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352
Hereditary Breast Cancer: The Era of New Susceptibility Genes
Apostolou, P., & Fostira, F. (2013) · BioMed Research International · doi:10.1155/2013/747318 · Cited by 351
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 336
Self-citationMolecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Buisson, R., Dion-Côté, A.-M., Coulombe, Y., Launay, H., Cai, H., Stasiak, A. Z., Stasiak, A., Xia, B., & Masson, J.-Y. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1915 · Cited by 307
PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
Zhang, F., Fan, Q., Ren, K., & Andreassen, P. R. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0123 · Cited by 306
Integrative genomic and transcriptomic analysis of leiomyosarcoma
Chudasama, P., Mughal, S. S., Sanders, M. A., Hübschmann, D., Chung, I., Deeg, K. I., Wong, S.-H., Rabe, S., Hlevnjak, M., Zapatka, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02602-0 · Cited by 306
Genetic Predisposition to Breast Cancer: Past, Present, and Future
Turnbull, C., & Rahman, N. (2008) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164339 · Cited by 302
Targeted therapy for cancer using PARP inhibitors
Lord, C. J., & Ashworth, A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.016 · Cited by 289
Self-citationOssovskaya, V., Koo, I. C., Kaldjian, E. P., Alvares, C., & Sherman, B. M. (2010) · Genes & Cancer · doi:10.1177/1947601910383418 · Cited by 269
Weigelt, B., Comino-Méndez, I., de Bruijn, I., Tian, L., Meisel, J. L., García-Murillas, I., Fribbens, C., Cutts, R., Martelotto, L. G., Ng, C. K. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0544 · Cited by 263
Drew, Y., Mulligan, E. A., Vong, W.-T., Thomas, H. D., Kahn, S., Kyle, S., Mukhopadhyay, A., Los, G., Hostomsky, Z., Plummer, E. R., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq509 · Cited by 261
A systematic review of the international prevalence of BRCA mutation in breast cancer
Armstrong, N., Ryder, S., Forbes, C., Ross, J., & Quek, R. G. (2019) · Clinical Epidemiology · doi:10.2147/clep.s206949 · Cited by 259
Homologous recombination deficiency and ovarian cancer
Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.005 · Cited by 258
Cancer and ageing: convergent and divergent mechanisms
Serrano, M., & Blasco, M. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2242 · Cited by 182
Bundred, N., Gardovskis, J., Jaskiewicz, J., Eglitis, J., Paramonov, V., McCormack, P., Swaisland, H., Cavallin, M., Parry, T., Carmichael, J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9922-7 · Cited by 89
Kim, S. I., Lee, M., Kim, H. S., Chung, H. H., Kim, J.-W., Park, N. H., & Song, Y.-S. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0511-7 · Cited by 75
Tassi, R. A., Todeschini, P., Siegel, E. R., Calza, S., Cappella, P., Ardighieri, L., Cadei, M., Bugatti, M., Romani, C., Bandiera, E., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0536-y · Cited by 67
The DNA damage response: balancing the scale between cancer and ageing.
Seviour, E. G., & Lin, S.-Y. (2010) · Aging · doi:10.18632/aging.100248 · Cited by 61
“As these processes are reviewed elsewhere [6-8], they will not be covered by this review.”
BackgroundHereditary breast cancer: From molecular pathology to tailored therapies
Tan, D. S. P., Marchiò, C., & Reis-Filho, J. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.057950 · Cited by 60
Historical Aspects of Xeroderma Pigmentosum and Nucleotide Excision Repair
Cleaver, J. E. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-09599-8_1 · Cited by 13
Metadata
- Authors
- Gudmundsdottir, K., & Ashworth, A.
- Venue
- Oncogene
- Published
- 2006-09-25
- Volume
- 25
- Issue
- 43
- Pages
- 5864-5874
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2062568878
- Cited by
- 622
- References
- 107
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.